[
  {
    "objectID": "projects.html",
    "href": "projects.html",
    "title": "Projects",
    "section": "",
    "text": "Dural Sinus Stenting in Pediatric IIH\n\n\n\ncode\n\n\nslides\n\n\nposter\n\n\n\n\nJun 14, 2024\n\n\n\n\n\nHost\n\n\n \n\n\n\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Mirindi Kabangu",
    "section": "",
    "text": "Thanks for checking out my web site!"
  },
  {
    "objectID": "DSS_prez.html#history",
    "href": "DSS_prez.html#history",
    "title": "Dural Sinus Stenting",
    "section": "History",
    "text": "History\n15-year-old girl with no PMHx\nPresents with chronic “throbbing headachs”\n\nHeadache Characteristics:\n\nSevere, throbbing headaches\nOccurs daily, lasting several hours\nWorsens with coughing or straining (Valsalva maneuver)\n\nVisual Disturbances:\n\nDouble vision (diplopia)\nTransient vision loss (lasting a few seconds to minutes)\n\nAuditory Symptoms:\n\nWhooshing sound in the ears (pulsatile tinnitus), particularly noticeable at night"
  },
  {
    "objectID": "DSS_prez.html#physical-examination",
    "href": "DSS_prez.html#physical-examination",
    "title": "Dural Sinus Stenting",
    "section": "Physical Examination",
    "text": "Physical Examination\n\n\n130/85 mmHg\n75 bpm\n16 breaths per minute\n98.6?F (37?C)\n85 kg (187 lbs)\n160 cm (5’3”)\nBMI: 33.2 kg/m?"
  },
  {
    "objectID": "DSS_prez.html#physical-examination-1",
    "href": "DSS_prez.html#physical-examination-1",
    "title": "Dural Sinus Stenting",
    "section": "Physical Examination",
    "text": "Physical Examination\n\n\n\n130/85 mmHg\n\n75 bpm\n16 breaths per minute\n98.6?F (37?C)\n85 kg (187 lbs)\n160 cm (5’3”)\nBMI: 33.2 kg/m?\n\n\nAlert and oriented, in no acute distress\n\n\nPapilledema observed on fundoscopic exam\n\n\nMild sixth nerve palsy (limited lateral eye movement)\n\n\nNormal strength and tone in all extremities\n\n\nIntact sensation to light touch and pinprick\n\n\n\n:::"
  },
  {
    "objectID": "DSS_prez.html#initial-presentation",
    "href": "DSS_prez.html#initial-presentation",
    "title": "Dural Sinus Stenting",
    "section": "Initial Presentation",
    "text": "Initial Presentation\nMeet Sarah, a 15-year-old girl who presents to the clinic with a three-month history of progressive headaches. Her headaches are described as severe, throbbing, and often accompanied by visual disturbances such as seeing double and experiencing transient vision loss. Additionally, Sarah reports hearing a whooshing sound in her ears that synchronizes with her heartbeat, particularly noticeable at night. Concerned about these symptoms, Sarah and her parents seek medical attention."
  },
  {
    "objectID": "DSS_prez.html#visit-to-the-primary-care-physician",
    "href": "DSS_prez.html#visit-to-the-primary-care-physician",
    "title": "Dural Sinus Stenting",
    "section": "Visit to the Primary Care Physician",
    "text": "Visit to the Primary Care Physician\nSarah’s primary care physician performs a comprehensive history and physical examination. Given her symptoms, Sarah is referred to an ophthalmologist for further evaluation of her visual complaints."
  },
  {
    "objectID": "DSS_prez.html#seeking-further-medical-attention",
    "href": "DSS_prez.html#seeking-further-medical-attention",
    "title": "Dural Sinus Stenting",
    "section": "Seeking Further Medical Attention",
    "text": "Seeking Further Medical Attention\nFollowing the discovery of papilledema, Sarah’s ophthalmologist refers her back to the primary care physician with a recommendation for neuroimaging and further evaluation by a neurologist."
  },
  {
    "objectID": "DSS_prez.html#diagnostic-imaging",
    "href": "DSS_prez.html#diagnostic-imaging",
    "title": "Dural Sinus Stenting",
    "section": "Diagnostic Imaging",
    "text": "Diagnostic Imaging\nSarah undergoes a brain MRI, which comes back normal, ruling out any masses or structural abnormalities. However, the MRV reveals stenosis of the transverse sinuses."
  },
  {
    "objectID": "DSS_prez.html#management-plan",
    "href": "DSS_prez.html#management-plan",
    "title": "Dural Sinus Stenting",
    "section": "Management Plan",
    "text": "Management Plan\nSarah’s lumbar puncture reveals an elevated opening pressure of 30 cm H2O, confirming the diagnosis of IIH. Initial management with acetazolamide 500 mg twice daily and lifestyle modifications is started."
  },
  {
    "objectID": "DSS_prez.html#persistent-symptoms",
    "href": "DSS_prez.html#persistent-symptoms",
    "title": "Dural Sinus Stenting",
    "section": "Persistent Symptoms",
    "text": "Persistent Symptoms\nDespite initial treatment with acetazolamide and lifestyle modifications, Sarah’s symptoms persist, and her vision continues to deteriorate."
  },
  {
    "objectID": "DSS_prez.html#counseling-on-treatment-options",
    "href": "DSS_prez.html#counseling-on-treatment-options",
    "title": "Dural Sinus Stenting",
    "section": "Counseling on Treatment Options",
    "text": "Counseling on Treatment Options\nSarah’s symptoms remain refractory to maximum medical therapy. She is counseled on further treatment options, including ventriculoperitoneal (VP) shunt and dural sinus stenting."
  },
  {
    "objectID": "DSS_prez.html#decision-and-procedure",
    "href": "DSS_prez.html#decision-and-procedure",
    "title": "Dural Sinus Stenting",
    "section": "Decision and Procedure",
    "text": "Decision and Procedure\nSarah opts for dural sinus stenting after discussing her options with her healthcare team. She is referred to an interventional radiologist and undergoes venous angiogram to evaluate for stenosis."
  },
  {
    "objectID": "DSS_prez.html#follow-up-and-outcome",
    "href": "DSS_prez.html#follow-up-and-outcome",
    "title": "Dural Sinus Stenting",
    "section": "Follow-Up and Outcome",
    "text": "Follow-Up and Outcome\nAfter the stenting procedure, Sarah’s symptoms significantly improve. Her headaches diminish, her vision is restored, and the pulsatile tinnitus resolves."
  },
  {
    "objectID": "DSS_prez.html#challenge-questions",
    "href": "DSS_prez.html#challenge-questions",
    "title": "Dural Sinus Stenting",
    "section": "Challenge Questions",
    "text": "Challenge Questions"
  },
  {
    "objectID": "DSS_prez.html#summary",
    "href": "DSS_prez.html#summary",
    "title": "Dural Sinus Stenting",
    "section": "Summary",
    "text": "Summary\n\nIIH is characterized by increased intracranial pressure without a detectable cause.\nDiagnosis involves imaging and lumbar puncture to measure opening pressure, following the latest guidelines.\nInitial management includes medication and lifestyle changes, with dural sinus stenting as an option for refractory cases, supported by current clinical guidelines."
  },
  {
    "objectID": "DSS_prez.html#about-this-presentation",
    "href": "DSS_prez.html#about-this-presentation",
    "title": "Dural Sinus Stenting",
    "section": "About This Presentation",
    "text": "About This Presentation\nThis educational resource was created to help surgical and neurological surgery residents prepare for their boards by learning about the diagnosis and management of idiopathic intracranial hypertension (IIH) through the journey of a patient case study.\nAuthor: Mirindi T. Kabangu\nContact: mkabangu@iu.edu"
  },
  {
    "objectID": "DSS_prez2.html#case",
    "href": "DSS_prez2.html#case",
    "title": "Dural Sinus Stenting",
    "section": "Case",
    "text": "Case\nChronic headaches\n\n\nCase was modified for teaching purposes"
  },
  {
    "objectID": "DSS_prez2.html#initial-presentation",
    "href": "DSS_prez2.html#initial-presentation",
    "title": "Dural Sinus Stenting",
    "section": "Initial Presentation",
    "text": "Initial Presentation\nMeet Sarah, a 15-year-old girl who presents to the clinic with a three-month history of progressive headaches."
  },
  {
    "objectID": "DSS_prez2.html#initial-presentation-1",
    "href": "DSS_prez2.html#initial-presentation-1",
    "title": "Dural Sinus Stenting",
    "section": "Initial Presentation",
    "text": "Initial Presentation\nMeet Sarah, a 15-year-old girl who presents to the clinic with a three-month history of progressive headaches.\n\n\n\n\n\n\nVital Signs\n120/80 mmHg\n78 bpm\n16 breaths per minute\n98.6°F (37°C)"
  },
  {
    "objectID": "DSS_prez2.html#initial-presentation-2",
    "href": "DSS_prez2.html#initial-presentation-2",
    "title": "Dural Sinus Stenting",
    "section": "Initial Presentation",
    "text": "Initial Presentation\nMeet Sarah, a 15-year-old girl who presents to the clinic with a three-month history of progressive headaches.\n\n\n\n\nVital Signs\n120/80 mmHg\n78 bpm\n16 breaths per minute\n98.6°F (37°C)\n\nPhysical Exam Findings\n\nDecreased visual acuity bilaterally\n\n\n\nPapilledema evident\n\n\n\nCranial nerves intact, no motor or sensory deficits\n\n\n\nWhooshing sound heard upon auscultation of the ear"
  },
  {
    "objectID": "DSS_prez2.html#visit-to-the-primary-care-physician",
    "href": "DSS_prez2.html#visit-to-the-primary-care-physician",
    "title": "Dural Sinus Stenting",
    "section": "Visit to the Primary Care Physician",
    "text": "Visit to the Primary Care Physician\nSarah’s primary care physician performs a comprehensive history and physical examination. Given her symptoms, Sarah is referred to an ophthalmologist for further evaluation of her visual complaints."
  },
  {
    "objectID": "DSS_prez2.html#seeking-further-medical-attention",
    "href": "DSS_prez2.html#seeking-further-medical-attention",
    "title": "Dural Sinus Stenting",
    "section": "Seeking Further Medical Attention",
    "text": "Seeking Further Medical Attention\nFollowing the discovery of papilledema, Sarah’s ophthalmologist refers her back to the primary care physician with a recommendation for neuroimaging and further evaluation by a neurologist."
  },
  {
    "objectID": "DSS_prez2.html#diagnostic-imaging",
    "href": "DSS_prez2.html#diagnostic-imaging",
    "title": "Dural Sinus Stenting",
    "section": "Diagnostic Imaging",
    "text": "Diagnostic Imaging\nSarah undergoes a brain MRI, which comes back normal, ruling out any masses or structural abnormalities. However, the MRV reveals stenosis of the transverse sinuses."
  },
  {
    "objectID": "DSS_prez2.html#management-plan",
    "href": "DSS_prez2.html#management-plan",
    "title": "Dural Sinus Stenting",
    "section": "Management Plan",
    "text": "Management Plan\nSarah’s lumbar puncture reveals an elevated opening pressure of 30 cm H2O, confirming the diagnosis of IIH. Initial management with acetazolamide 500 mg twice daily and lifestyle modifications is started."
  },
  {
    "objectID": "DSS_prez2.html#persistent-symptoms",
    "href": "DSS_prez2.html#persistent-symptoms",
    "title": "Dural Sinus Stenting",
    "section": "Persistent Symptoms",
    "text": "Persistent Symptoms\nDespite initial treatment with acetazolamide and lifestyle modifications, Sarah’s symptoms persist, and her vision continues to deteriorate."
  },
  {
    "objectID": "DSS_prez2.html#counseling-on-treatment-options",
    "href": "DSS_prez2.html#counseling-on-treatment-options",
    "title": "Dural Sinus Stenting",
    "section": "Counseling on Treatment Options",
    "text": "Counseling on Treatment Options\nSarah’s symptoms remain refractory to maximum medical therapy. She is counseled on further treatment options, including ventriculoperitoneal (VP) shunt and dural sinus stenting."
  },
  {
    "objectID": "DSS_prez2.html#decision-and-procedure",
    "href": "DSS_prez2.html#decision-and-procedure",
    "title": "Dural Sinus Stenting",
    "section": "Decision and Procedure",
    "text": "Decision and Procedure\nSarah opts for dural sinus stenting after discussing her options with her healthcare team. She is referred to an interventional radiologist and undergoes venous angiogram to evaluate for stenosis."
  },
  {
    "objectID": "DSS_prez2.html#follow-up-and-outcome",
    "href": "DSS_prez2.html#follow-up-and-outcome",
    "title": "Dural Sinus Stenting",
    "section": "Follow-Up and Outcome",
    "text": "Follow-Up and Outcome\nAfter the stenting procedure, Sarah’s symptoms significantly improve. Her headaches diminish, her vision is restored, and the pulsatile tinnitus resolves."
  },
  {
    "objectID": "DSS_prez2.html#challenge-questions",
    "href": "DSS_prez2.html#challenge-questions",
    "title": "Dural Sinus Stenting",
    "section": "Challenge Questions",
    "text": "Challenge Questions"
  },
  {
    "objectID": "DSS_prez2.html#summary",
    "href": "DSS_prez2.html#summary",
    "title": "Dural Sinus Stenting",
    "section": "Summary",
    "text": "Summary\n\nIIH is characterized by increased intracranial pressure without a detectable cause.\nDiagnosis involves imaging and lumbar puncture to measure opening pressure, following the latest guidelines.\nInitial management includes medication and lifestyle changes, with dural sinus stenting as an option for refractory cases, supported by current clinical guidelines."
  },
  {
    "objectID": "DSS_prez2.html#authors",
    "href": "DSS_prez2.html#authors",
    "title": "Dural Sinus Stenting",
    "section": "Authors",
    "text": "Authors\nAuthors: Mirindi T. Kabangu & Noor U. Malik\nContact: mkabangu@iu.edu & noumalik@iu.edu\n\n\n\n\nBack to Site"
  },
  {
    "objectID": "posts/2024-surgery-research-day/index.html",
    "href": "posts/2024-surgery-research-day/index.html",
    "title": "Dural Sinus Stenting in Pediatric IIH",
    "section": "",
    "text": "This study involved a diverse cohort of pediatric patients diagnosed with Idiopathic Intracranial Hypertension (IIH), focusing on those who underwent evaluation for venous sinus stenting. The demographic breakdown is detailed in the table below, which includes age, sex, puberty stage, and BMI percentile.\n\nAge: IIH in pediatric patients is influenced significantly by age. Younger children often present with nonspecific symptoms, making the diagnosis challenging, whereas older children may display more classic symptoms of IIH like headaches and visual disturbances. The treatment and prognosis can also vary with age, making it a crucial demographic factor in studying and managing IIH.\nSex Distribution: The prevalence and characteristics of IIH can differ between sexes, particularly during adolescence. Females, especially post-pubertal, are more frequently affected, which might relate to hormonal changes that affect intracranial pressure and venous sinus dynamics. This makes sex an important variable in analyzing the efficacy of treatments like venous sinus stenting.\nPuberty Stage: Changes during puberty, especially in overweight children, can increase the risk of developing IIH. Understanding the stage of puberty can help in correlating the severity and presentation of symptoms with the physiological changes occurring during this period.\nBMI Percentile: Obesity is a well-recognized risk factor for IIH, particularly in older children and adolescents. The BMI percentile provides a measure of relative body weight and is critical for identifying at-risk pediatric patients. Higher BMI percentiles are associated with an increased risk of IIH, likely due to increased venous pressure and alterations in cerebrospinal fluid dynamics. This makes BMI percentile a significant factor in both the study and management of pediatric II\n\nUnderstanding these demographic factors is essential for evaluating the impact of venous sinus stenting and its efficacy across different subgroups within the pediatric population. This comprehensive demographic analysis serves as the foundation for further detailed outcomes analysis presented later.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall, N = 201\nStented, N = 101\nNon-Stented, N = 101\np-value2\n\n\n\n\nAge\n14 (11, 16)\n15 (12, 16)\n13 (9, 16)\n0.6\n\n\nPuberty stage\n\n\n\n\n\n\n0.6\n\n\n    pre\n8 (40%)\n3 (30%)\n5 (50%)\n\n\n\n\n    post\n12 (60%)\n7 (70%)\n5 (50%)\n\n\n\n\nSex\n\n\n\n\n\n\n&gt;0.9\n\n\n    Female\n13 (65%)\n7 (70%)\n6 (60%)\n\n\n\n\n    Male\n7 (35%)\n3 (30%)\n4 (40%)\n\n\n\n\nBMI (percentile)\n97 (90, 99)\n99 (95, 99)\n95 (90, 97)\n0.079\n\n\nHeadache\n19 (95%)\n10 (100%)\n9 (90%)\n&gt;0.9\n\n\nVision changes\n10 (50%)\n5 (50%)\n5 (50%)\n&gt;0.9\n\n\nDiplopia\n4 (20%)\n1 (10%)\n3 (30%)\n0.6\n\n\nPapilledema\n17 (85%)\n9 (90%)\n8 (80%)\n&gt;0.9\n\n\nTinnitus\n10 (50%)\n5 (50%)\n5 (50%)\n&gt;0.9\n\n\nOpening pressure (mmHg)\n32 (25, 40)\n33 (31, 39)\n26 (18, 41)\n0.4\n\n\n\n1 Median (IQR); n (%)\n\n\n2 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test\n\n\n\n\n\n\n\n\nPreliminary statistical analyses were conducted to assess demographic differences between the stented and non-stented groups among pediatric patients with Idiopathic Intracranial Hypertension. The results indicated that there were no significant differences in age between the two groups (p = 0.6). Similarly, no significant differences in BMI percentiles between the groups (p = 0.08) nor categorical variables such as sex (p &gt; 0.9) and puberty stage (p = 0.6)."
  },
  {
    "objectID": "posts/2024-surgery-research-day/index.html#patient-demographics-overview",
    "href": "posts/2024-surgery-research-day/index.html#patient-demographics-overview",
    "title": "Dural Sinus Stenting in Pediatric IIH",
    "section": "",
    "text": "This study involved a diverse cohort of pediatric patients diagnosed with Idiopathic Intracranial Hypertension (IIH), focusing on those who underwent evaluation for venous sinus stenting. The demographic breakdown is detailed in the table below, which includes age, sex, puberty stage, and BMI percentile.\n\nAge: IIH in pediatric patients is influenced significantly by age. Younger children often present with nonspecific symptoms, making the diagnosis challenging, whereas older children may display more classic symptoms of IIH like headaches and visual disturbances. The treatment and prognosis can also vary with age, making it a crucial demographic factor in studying and managing IIH.\nSex Distribution: The prevalence and characteristics of IIH can differ between sexes, particularly during adolescence. Females, especially post-pubertal, are more frequently affected, which might relate to hormonal changes that affect intracranial pressure and venous sinus dynamics. This makes sex an important variable in analyzing the efficacy of treatments like venous sinus stenting.\nPuberty Stage: Changes during puberty, especially in overweight children, can increase the risk of developing IIH. Understanding the stage of puberty can help in correlating the severity and presentation of symptoms with the physiological changes occurring during this period.\nBMI Percentile: Obesity is a well-recognized risk factor for IIH, particularly in older children and adolescents. The BMI percentile provides a measure of relative body weight and is critical for identifying at-risk pediatric patients. Higher BMI percentiles are associated with an increased risk of IIH, likely due to increased venous pressure and alterations in cerebrospinal fluid dynamics. This makes BMI percentile a significant factor in both the study and management of pediatric II\n\nUnderstanding these demographic factors is essential for evaluating the impact of venous sinus stenting and its efficacy across different subgroups within the pediatric population. This comprehensive demographic analysis serves as the foundation for further detailed outcomes analysis presented later.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall, N = 201\nStented, N = 101\nNon-Stented, N = 101\np-value2\n\n\n\n\nAge\n14 (11, 16)\n15 (12, 16)\n13 (9, 16)\n0.6\n\n\nPuberty stage\n\n\n\n\n\n\n0.6\n\n\n    pre\n8 (40%)\n3 (30%)\n5 (50%)\n\n\n\n\n    post\n12 (60%)\n7 (70%)\n5 (50%)\n\n\n\n\nSex\n\n\n\n\n\n\n&gt;0.9\n\n\n    Female\n13 (65%)\n7 (70%)\n6 (60%)\n\n\n\n\n    Male\n7 (35%)\n3 (30%)\n4 (40%)\n\n\n\n\nBMI (percentile)\n97 (90, 99)\n99 (95, 99)\n95 (90, 97)\n0.079\n\n\nHeadache\n19 (95%)\n10 (100%)\n9 (90%)\n&gt;0.9\n\n\nVision changes\n10 (50%)\n5 (50%)\n5 (50%)\n&gt;0.9\n\n\nDiplopia\n4 (20%)\n1 (10%)\n3 (30%)\n0.6\n\n\nPapilledema\n17 (85%)\n9 (90%)\n8 (80%)\n&gt;0.9\n\n\nTinnitus\n10 (50%)\n5 (50%)\n5 (50%)\n&gt;0.9\n\n\nOpening pressure (mmHg)\n32 (25, 40)\n33 (31, 39)\n26 (18, 41)\n0.4\n\n\n\n1 Median (IQR); n (%)\n\n\n2 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test\n\n\n\n\n\n\n\n\nPreliminary statistical analyses were conducted to assess demographic differences between the stented and non-stented groups among pediatric patients with Idiopathic Intracranial Hypertension. The results indicated that there were no significant differences in age between the two groups (p = 0.6). Similarly, no significant differences in BMI percentiles between the groups (p = 0.08) nor categorical variables such as sex (p &gt; 0.9) and puberty stage (p = 0.6)."
  },
  {
    "objectID": "posts/2024-surgery-research-day/index.html#resolution-of-symptoms",
    "href": "posts/2024-surgery-research-day/index.html#resolution-of-symptoms",
    "title": "Dural Sinus Stenting in Pediatric IIH",
    "section": "Resolution of Symptoms",
    "text": "Resolution of Symptoms\nIn pediatric patients with Idiopathic Intracranial Hypertension (IIH), symptom resolution following therapeutic interventions such as venous sinus stenting is a critical measure of treatment efficacy. Studies have shown that interventions aiming to reduce intracranial pressure can lead to significant improvement or complete resolution of primary symptoms, including headaches, visual disturbances, and papilledema. For instance, venous sinus stenting has been reported to alleviate symptoms in a substantial proportion of patients by improving venous outflow, thus reducing intracranial pressure. This outcome not only suggests an immediate relief from the debilitating symptoms associated with IIH but also indicates a potential long-term benefit in preventing further complications such as vision loss. The efficacy of stenting in symptom resolution underscores its value as a viable alternative to traditional medical and surgical treatments, which might not be effective or feasible for all patients.\n\n\n\n\n\n\n\n\n\nThe bar chart illustrates the proportion of pediatric patients with Idiopathic Intracranial Hypertension (IIH) experiencing symptom resolution post-treatment, categorized by stenting status. Each symptom—headache, vision changes, diplopia, papilledema, and tinnitus—is analyzed separately. The results clearly indicate that patients who received venous sinus stenting generally show a higher rate of symptom resolution compared to those who were not stented. This is particularly evident for symptoms such as headaches and papilledema, which are critical indicators of the severity of IIH.\nThe differential impact across various symptoms and between treatment groups underscores the need for a tailored approach in managing IIH. These findings advocate for considering venous sinus stenting as a viable treatment option, especially in cases where conventional medical management does not yield sufficient symptom control. This analysis thus provides compelling evidence supporting the targeted use of stenting in pediatric IIH patients, potentially guiding more personalized and effective treatment strategies."
  },
  {
    "objectID": "posts/2024-surgery-research-day/index.html#continuous-use-of-hydrochlorothiazide",
    "href": "posts/2024-surgery-research-day/index.html#continuous-use-of-hydrochlorothiazide",
    "title": "Dural Sinus Stenting in Pediatric IIH",
    "section": "Continuous Use of Hydrochlorothiazide",
    "text": "Continuous Use of Hydrochlorothiazide\nIn typical studies and clinical reports, it’s noted that successful venous stenting can lead to a reduction in intracranial pressure, which might decrease the need for medications used to manage this condition. If a stent effectively alleviates the venous outflow obstruction that contributes to IIH, patients might experience symptom relief that could reduce or eliminate the need for continuous medical therapy.\n\n\n\n\n\n\n\n\n\nOur analysis reveals that there are no significant differences in the continued use of hydrochlorothiazide between stented and non-stented patients at follow-up. This outcome was visualized in a bar chart showing the average continuation rates of hydrochlorothiazide across both groups, emphasizing that stenting does not appear to influence the necessity for ongoing medication usage in the context of managing IIH symptoms or related conditions. These findings suggest that while stenting may address certain physiological aspects of IIH, such as venous outflow, it does not universally negate the need for pharmacological intervention such as hydrochlorothiazide. This insight is crucial for clinicians as it underscores the importance of a comprehensive treatment approach that may still require medication management even when procedural interventions like stenting are employed."
  },
  {
    "objectID": "posts/2024-surgery-research-day/index.html#surgical-interventions-post-procedure",
    "href": "posts/2024-surgery-research-day/index.html#surgical-interventions-post-procedure",
    "title": "Dural Sinus Stenting in Pediatric IIH",
    "section": "Surgical Interventions Post-Procedure",
    "text": "Surgical Interventions Post-Procedure\nWhile stenting often leads to substantial improvements, its effectiveness varies, with some patients experiencing incomplete symptom resolution. This variability underscores the necessity for ongoing assessments to determine if additional interventions, such as cerebrospinal fluid (CSF) shunting, are required.\n\n\n\n\n\n\n\n\n\nNotably, a smaller proportion of the stented group required VP shunts compared to the non-stented group, suggesting that stenting might be mitigating the underlying conditions necessitating further surgical interventions. This outcome highlights the potential of stenting not only in alleviating symptoms but also in reducing the surgical burden on patients. By lessening the need for additional procedures like VP shunts, stenting could represent a significant advancement in the treatment paradigm for IIH, offering a less invasive and possibly more cost-effective approach to long-term management of the disease."
  },
  {
    "objectID": "posts/2024-surgery-research-day/index.html#linear-regression-analysis",
    "href": "posts/2024-surgery-research-day/index.html#linear-regression-analysis",
    "title": "Dural Sinus Stenting in Pediatric IIH",
    "section": "Linear Regression Analysis",
    "text": "Linear Regression Analysis\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFollowing the logistic regression analysis, the results suggest that higher BMI percentiles and the use of stenting significantly predict symptom resolution in pediatric patients with idiopathic intracranial hypertension (IIH), while age has a less pronounced effect. Specifically, the analysis indicates that patients with higher BMI percentiles are more likely to experience symptom resolution, highlighting the importance of body mass index as a factor in treatment outcomes. Moreover, stenting emerges as a critical intervention that markedly improves the likelihood of resolving symptoms compared to non-stented patients. This suggests that stenting not only alleviates the mechanical obstructions causing increased intracranial pressure but also leads to better clinical outcomes. In contrast, age does not show a strong influence on symptom resolution, indicating that younger and older pediatric patients are likely to benefit similarly from interventions aimed at reducing intracranial pressure. These findings underscore the effectiveness of targeted treatments like stenting in managing IIH and emphasize the need for tailored therapeutic strategies based on individual patient characteristics such as BMI."
  }
]